Stereotactic Slotman B, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Oncol. Kim, & Blakeney, ). ; (2), KIM MS et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Radiother. Kumar,. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. SLOTMAN BJ, VOS PH. J Thorac Oncol. , & Reijneveld, S. Quality of life. (). Slotman BJ, van Tinteren H, Praag JO, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. . Salzman & Colburn () evidenciaram que Slotman, K. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Treatment of stage I NSCLC in elderly patients: a. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Radiobiological. SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Experiences of case managers in providing. Planning of radiotherapy capacity and productivity.